Dr Mirco Meniconi graduated with a Doctorate from the University of Perugia in 2005. He then went on to work at GlaxoSmithKlein (GSK) for two years, before moving to Evotec in 2007 as a Senior Scientist in the Computer Aided Drug Design team. After spending 13 years working in industry, Dr Meniconi joined the ICR in 2018 as the Head of In-Silico Medicinal Chemistry in the Cancer Therapeutics division.
The goal of the In-Silico Medicinal Chemistry team is to accelerate the progression of drug discovery projects in the CR-UK Cancer Therapeutics Unit portfolio by appropriate application of in silico methods. The team operates during all phases of drug discovery, from hit identification, through hit-to-lead, lead-optimisation, until the delivery of a clinical candidate.
The team's main research areas and activities include:
– Structure-based Drug Design, with a particular focus on in-silico docking and virtual screen.
– Ligand based Drug Design: 3D shape/pharmacophore similarity, 2D similarity, pharmacophore elucidation, scaffold hopping.
– Advanced modelling techniques such as molecular dynamics, quantum chemistry, and water analysis.
– QSAR, Machine learning, Modelling of ADMET properties.
– Data analysis and visualisation.
– HTS analysis and hit triage, Compounds library design and acquisition.
– High Performance Computing and Method development.